Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372
Phase 2 small_molecule active
Quick answer
Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372 for Non-small cell lung cancer (NSCLC) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Non-small cell lung cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active